Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference

« back

SEATTLE – Dec. 06, 2023 Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced that it will participate in the 2023 RBC Capital Markets Healthcare Private Company Conference, being held virtually December 13-14, 2023.

Lyn Baranowski, chief executive officer of Avalyn, will provide a corporate overview presentation and participate in a fireside chat on Wednesday, December 13, 2023, at 4:30 p.m. ET. Company management will also participate in virtual one-on-one meetings with investors at the conference.

About Avalyn Pharma
Avalyn is a biopharmaceutical company developing targeted therapeutics for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit

Alex Straus
THRUST Strategic Communications

Cara Mayfield
THRUST Strategic Communications